NCT02862587

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Shanghai International Medical Center · Industry
• Sex: All
• Age: 18 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.

Detailed description

A total of 40 patients may be enrolled over a period of 1-2 years.

Conditions

• Precision Cells
• Chemotherapy
• Advanced Lung Cancer

Interventions

Type	Name	Description
DRUG	Chemotherapy	Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
BIOLOGICAL	precision cells	precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-03-01
• Completion: 2018-08-01
• First posted: 2016-08-11
• Last updated: 2016-09-02

Locations

1 site across 1 country: China